[Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.] jetcityimage Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) said a new analysis showed its oral weight-loss drug Foundayo (orforglipron) 17.2 mg delivered significantly greater weight loss and improved blood sugar control compared with oral semaglutide 25 mg in adults with type 2 diabetes. The findings [https://seekingalpha.com/pr/20666648-lillys-foundayo-orforglipron-17_2-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral], presented at the European Association for the Study of Diabetes meeting in Milan, are based on an indirect treatment comparison using data from the ACHIEVE-3 and PIONEER PLUS trials. At 52 weeks, patients taking Foundayo 17.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.